We are thus in the unsatisfying position of making cross-trial comparisons, which are fraught with the problems of varying trial design (Figure 1), varying patient populations, and variability in eligibility based on tumour size, axillary node status, and HER2 assessment method (Table I). Here, ERBB2 is linked to neoplasm.